US2018161309A1PendingUtilityA1
Methods and compositions involving (s)-bucindolol
Est. expiryAug 1, 2028(~2 yrs left)· nominal 20-yr term from priority
A61P 9/12A61P 9/04A61P 9/06A61P 25/06A61P 29/00A61P 27/06A61P 11/00A61B 17/80A61K 45/06A61B 17/72A61M 25/0045A61L 27/54A61F 2/0063A61K 31/4045A61L 29/16A61F 2/06A61B 17/1214A61B 17/86A61F 2250/0067C07D 209/14A61F 2/82A61B 17/04A61L 31/16A61L 2300/204A61F 2/24A61F 2/01
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.
Claims
exact text as granted — not AI-modified1 .- 46 . (canceled)
47 . A method of increasing the capacity of a cell to generate NO, comprising contacting said cell with a composition comprising a pharmaceutically acceptable carrier and bucindolol substantially free of its R-stereoisomer.
48 . The method of claim 47 , wherein the cell is an endothelial cell, an epithelial cell, or a stem cell.
49 . The method of claim 47 , wherein the cell is an endothelial cell.
50 . The method of claim 47 , wherein the cell is in a patient.
51 . The method of claim 47 , wherein the cell is in an animal.
52 . The method of claim 51 , wherein the animal is a mouse, a rat, a rabbit, a cat, a dog, a horse, a sheep, a goat, a cow, or a primate.
53 .- 62 . (canceled)Join the waitlist — get patent alerts
Track US2018161309A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.